Anthony Quinn, SVP, Chief Medical Officer at SYNAGEVA BIOPHARMA CORP (GEVA), sold 26,000 shares at $40.65 ($1.1M) on 2012-06-25, disclosed to the SEC on 2012-06-27.
Scheduled sale ($1.1M) by SVP, Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| GEVA | SELL | 2015-04-23 | $1.1M | — | Filing → |
| GEVA | SELL | 2015-04-17 | $1.1M | — | Filing → |
| GEVA | SELL | 2015-04-08 | $2.8M | — | Filing → |